Inglis Tiffany Eul Davis 4

4 · SERA PROGNOSTICS, INC. · Filed Mar 13, 2026

AI-generated summary of this filing

Updated Mar 13, 2026

SERA CMO Tiffany Inglis Receives RSU and Option Awards

What Happened

Inglis Tiffany Eul Davis, Chief Medical Officer of SERA Prognostics, received equity awards on 2026-03-12: 17,437 restricted stock units (RSUs) and 27,034 derivative awards (stock options). Both grants show $0 cash paid in the report (they are compensation grants, not open-market trades).

Key Details

Transaction date(s): 2026-03-12; Form 4 filed 2026-03-13 (timely).
Prices: $0.00 reported (awarded, not purchased).
Vesting/terms:
- RSUs (17,437): vest over four years — 1/16 of the original grant vests in quarterly installments starting on the vesting commencement date of March 10, 2026, subject to continued service. (Footnote F1)
- Stock options (27,034): vest over four years — 1/48 of the original grant vests in monthly installments starting on March 10, 2026, subject to continued service. (Footnote F2)
Shares owned after transaction: not specified in the provided filing excerpt.
Filing timeliness: Reported promptly the next day; no late-filing flag indicated.

Context

These awards are compensation grants (not purchases or sales). RSUs convert to actual shares as they vest; options must be exercised (and may require payment of a strike price) before becoming shares. There is no indication the grants were immediately sold or exercised. These kinds of awards are routine executive compensation and do not by themselves indicate buying or selling sentiment.

Form 4

Period: 2026-03-12

Chief Medical Officer

Transactions

Award
Class A Common Stock
[F1]
2026-03-12+17,437→ 92,437 total
Award
Stock Option (right to buy)
[F2]
2026-03-12+27,034→ 27,034 total
Exercise: $1.99Exp: 2036-03-12→ Class A Common Stock (27,034 underlying)

Footnotes (2)

[F1]Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 1/16 of the original grant amount vests in quarterly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.
[F2]These stock options vest over four years as follows: 1/48 of the original grant amount vests in monthly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.

Signature

/s/ Benjamin G. Jackson, Attorney-in-fact|2026-03-13

1 file